Loading

Please wait...

Myrbetriq

Generic Name: mirabegron (MIR a BEG ron)
Brand Names: Myrbetriq
Myrbetriq (mirabegron) is used to treat overactive bladder with symptoms of frequent or urgent urination and urinary incontinence. Includes Myrbetriq side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Myrbetriq

Set your location
for drug prices near you

Enter your zip code

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Myrbetriq (mirabegron) relaxes the muscles of the urinary bladder, reducing bladder spasms. Myrbetriq is used to treat the symptoms of overactive bladder, such as frequent or urgent urination and urinary incontinence. Myrbetriq is often used in combination with another overactive bladder medicine, solifeNacin. Myrbetriq may also be used for purposes not listed in this medication guide. You should not use Myrbetriq if you have A condition called angioedema can occur after taking Myrbetriq. Angioedema is a condition that leads to face, lip, tongue, throat swelling, difficulty breathing and can be fatal. Seek emergency attention immediately if these symptoms occur. Learn more

Myrbetriq Medicare Coverage

Overview

Does Medicare cover Myrbetriq?

Yes

100% of Medicare Part D and Medicare Advantage plans cover this drug.
How much is my Myrbetriq co-pay with Medicare?

It depends. Which coverage stage are you in? Click on a tab below…

CO-PAY RANGE

$42 – $417

In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.

Ways to Save on Myrbetriq

Here are some ways that may lower the cost of your myrbetriq prescription.

  • Instead of Medicare, Use a USA Rx Coupon

    If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.

Myrbetriq Side Effects

Myrbetriq Side Effects

Note: This document contains side effect information about mirabegron. Some of the dosage forms listed on this page may not apply to the brand name Myrbetriq.

In Summary

Common side effects of Myrbetriq include: hypertension. Other side effects include: urinary tract infection. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to mirabegron: oral tablet extended release

Along with its needed effects, mirabegron (the active ingredient contained in Myrbetriq) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking mirabegron:

More common

  • Bladder pain
  • bloody or cloudy urine
  • blurred vision
  • difficult, burning, or painful urination
  • dizziness
  • frequent urge to urinate
  • headache
  • lower back or side pain
  • nervousness
  • pounding in the ears
  • slow, fast, or irregular heartbeat

Rare

  • Blindness
  • decrease in vision
  • eye pain
  • lower abdominal or stomach pain
  • nausea
  • pain in the groin or genitals
  • tearing or eyes
  • vomiting

Incidence not known

  • Blistering, peeling, or loosening of the skin
  • chills
  • cough
  • decrease in the frequency of urination
  • decrease in urine volume
  • diarrhea
  • difficulty in passing urine (dribbling)
  • itching
  • joint or muscle pain
  • large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • unusual tiredness or weakness

Some side effects of mirabegron may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Back pain
  • body aches or pain
  • difficulty having a bowel movement
  • difficulty with breathing
  • difficulty with moving
  • dry mouth
  • ear congestion
  • fever
  • loss of voice
  • muscle ache or stiffness
  • sneezing
  • stomach pain
  • stuffy or runny nose

Rare

  • Belching
  • burning feeling in the chest or stomach
  • full or bloated feeling
  • heartburn
  • hives or welts, skin rash
  • indigestion
  • itching or pain of the vagina or genital area
  • pain or tenderness around the eyes and cheekbones
  • pressure in the stomach
  • redness of the skin
  • stomach discomfort, upset, or tenderness
  • swelling of the lips
  • thick, white vaginal discharge with mild or no odor

For Healthcare Professionals

Applies to mirabegron: oral tablet extended release

General

The more commonly reported adverse reactions have included hypertension, nasopharyngitis, urinary tract infection, and headache.

Cardiovascular

Very common (10% or more): Hypertension (up to 11.3%)

Common (1% to 10%): Tachycardia

Uncommon (0.1% to 1%): Atrial fibrillation, palpitations, worsening of preexisting hypertension

In 2 randomized controlled studies, dose-related increases in supine blood pressure occurred. At the maximum recommended dose of 50 mg per day, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mm Hg.

Dermatologic

Uncommon (0.1% to 1%): Urticaria, rash, pruritus, lip edema, macular rash, papular rash

Rare (less than 0.1%): Leukocytoclastic vasculitis, purpura, angioedema

Angioedema of the face, lips, tongue, and/or larynx has been reported. In some case, this occurred after the first dose or after multiple doses.

Gastrointestinal

Common (1% to 10%): Nausea, constipation, diarrhea, abdominal pain

Uncommon (0.1% to 1%): Dyspepsia, gastritis, abdominal distension

Rare (less than 0.1%): Lip edema

Genitourinary

Common (1% to 10%): Urinary tract infection

Uncommon (0.1% to 1%): Nephrolithiasis, bladder pain, cystitis, vaginal infection, vulvovaginal pruritus

Postmarketing reports: Urinary retention

Urinary retention has been reported in patients with bladder outlet obstruction (BOO) and in patients taking muscarinic antagonists for the treatment of overactive bladder. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in patient taking this drug.

Musculoskeletal

Common (1% to 10%): Arthralgia

Uncommon (0.1% to 1%): Joint swelling

Nervous system

Common (1% to 10%): Headache, fatigue, dizziness

Ocular

Uncommon (0.1% to 1%): Glaucoma, blurred vision, dry eyes

Rare (less than 0.1%): Eyelid edema

Oncologic

Rare (less than 0.1%): Prostate cancer

Respiratory

Common (1% to 10%): Nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis

Hepatic

Uncommon (0.1% to 1%): Increased ALT, AST, and GGT

Psychiatric

The majority of patients reporting confusion, hallucinations, insomnia, and anxiety had preexisting conditions or were using concomitant medications that may have contributed to these events.

Postmarketing reports: Confusion, hallucinations, insomnia, anxiety

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Myrbetriq (www.drugs.com/myrbetriq.html).